Want to join the conversation?
$AGN and $ADMS announced U.S. availability of new dosage strengths for Namzaric (Memantine and Donepezil Hydrochlorides) extended release for the treatment of moderate to severe Alzheimer's disease. Namzaric's new indication and dosage strengths were approved by the FDA in July 2016.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.